Harmony Biosciences (HRMY) Tops Q2 EPS by 15c
Tweet
Share
E-mail
Get Alerts HRMY Hot Sheet
Join SI Premium – FREE
Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.76, $0.15 better than the analyst estimate of $0.61. Revenue for the quarter came in at $134.2 million versus the consensus estimate of $142.02 million.
For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
- Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
